tbuckley/cabot-search huggingface dataset:
FRI0158 Clinical Evaluation Usefulness of Standardized Protocol Strategies of Dose Reduction in Patients with Rheumatoid Arthritis in Clinical Remission Treated with Biologic Therapies. The Optibio Study
Authors: C. Bejerano, N. Oreiro, C. Fernandez-Lopez, J.A. Pinto-Tasende, A. Atanes, B. Aspe, G. Graña, M. Freire, M. Acasuso, J. De Toro, F.J. Blanco
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> The OPTIBIO study is a clinical trial whose primary endpoint is to evaluate the proportion of patients that after one year are maintained in clinical remission with a dose reduction treatment regimen of biological therapy in patients with Rheumatoid Arthritis, and to evaluate if the proportion of patients in remission with new regimen dose of treatment is not inferior to patients in remission with standard dose regimen. In our present work, we describe the preliminary results obtained so far. <h3>Methods</h3> Open, randomized and controlled study of patients in clinical remission (DAS 28 &lt;2.6 or SDAI &lt;5 or ACR/EULAR 2011 criteria) at least 6 months followed in Third level Hospital Rheumatology Department. Patients treated with TNF inhibitors therapies (Etanercept, Infliximab, Adalimumab, Certolizumab, Golimumab), Tocilizumab and Abatacept. Patients are assigned to two groups randomly. Intervention group: according to a standardized protocol of dose reduction of biological therapies. Control group: according to standard dose regimen. Flare is considered when DAS28&gt;2.6 or SDAI&gt;5 or ACR/EULAR criteria are not fulfilled. Patients are following during after a minimum period of one year and maximum period of 3 years. The frequency of visits is every 12 weeks. <h3>Results</h3> 58 patients have been included from 14 April 2014 to 11 January 2016. Forty-eight women (82,76%) and 10 men (17,24%) with an average age of 59,34 ± 11,28 years. Twenty-nine in standard regimen dose and 29 patients in dose reduction regimen. None of the patients had tender or swollen joints at the beginning. At baseline, ESR and CRP values were 16,84 mm/1hour y 0,22 mg/dl respectively. DAS 28-ESR value was 1,84 ± 0.72 and DAS28-CRP was 1.34 ± 0.26. Rheumatoid Factor is positive in 79.31%. Forty-one patients have erosive disease. Seventeen patients have presented a flare: 24,13% in control group and 34,48% in intervention group without statistical signification (p=0.5640). The characteristics of the patients are described in table 1. Statistic differences were not found. <h3>Conclusions</h3> Preliminary results show that dose reduction of biological therapies with a standardized protocol it does not seem to increase reactivation risk of disease activity. <h3>Disclosure of Interest</h3> None declared
Requirements for Retroviral Targeting of a Suicide Gene to Alloreactive Memory Stem T Cells for Adoptive Immunotherapy of Leukemia.
Authors: Attilio Bondanza, Lothar Hambach, Shin Kaneko, Sara Mastaglio, Bart Nijmeijer, Astrid Van Halteren, Maurilio Ponzoni, Luca Aldrighetti, Salvatore Toma, Marina Radrizzani, Fabio Ciceri, Claudio Bordignon, Els Goulmy, Chiara Bonini
Journal: Blood (2007)
Gene Expression and Mutation Analysis (GEMA) –Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK –Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells
Authors: Margaret Nieborowska-Skorska, Katherine Sullivan, Paulina Podszywalow-Bartnicka, Grazyna Hoser, Elisabeth Bolton-Gillespie, Kimberly Cramer-Morales, Artur Slupianek, Chun Zhou, Sabine Cerny-Reiterer, Tomasz Stoklosa, Stephen M. Sykes, Peter Valent, Curt I. Civin, Markus Muschen, Mark D. Minden, Kolja Eppert, Tomasz Skorski
Journal: Blood (2014)
Pre-Operative Cytokine-Induced Mobilization of Bone Marrow-Derived Cells, Followed by Revascularization Surgery: Early and Long-Term Results of a Prospective Study in Patients with End-Stage Ischemic Cardiac Disease
Authors: Guglielmo M Actis Dato, Fabrizio Sansone, Edoardo Zingarelli, Roberto Flocco, Giuseppe Punta, Francesco Parisi, Pier Giuseppe Forsennati, Gian Luca Bardi, Stefano del Ponte, Riccardo Casabona, Corrado Tarella
Journal: Blood (2011)
THU0468 Osteoporosis and Osteocalcin Levels in Patients with Gout: Table 1.
Authors: A. Doğru, A. Balkarlı, C.C. Karatay, V. Cobankara, M. Sahin, S.E. Tunc
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout is a rheumatic disease characterized by the deposition of monosodium urate crystals in the joints and surrounding tissues. Gout is the most common inflammatory arthritis in men. It affects 1–2% of the adult population. Comorbid conditions and drugs used in gout are thought to increase the risk of osteoporosis but unlike some other forms of rheumatic diseases, gout is not believed to cause osteoporosis. <h3>Objectives</h3> In our study, we aimed to investigate the osteoporosis and osteocalsin levels in patients with gout. <h3>Methods</h3> 70 patients diagnosed with gout and 53 age-sex match controls were included in the study. Cardiovascular diseases, chronic renal disease, diabetes mellitus, hypertension, thyroid disease, bone disorders, eating disorders, gastrointestinal surgery or disease history, steroid use, alcohol use, patients with family history of osteoporotic fracture were excluded. The t and z scores from lumbar spine (L2-L4) and femur (neck, ward, trochanter, total) were determined by Dual energy X-ray absorptiometry (DEXA). Osteocalcin levels was measured by electrochemiluminescent immunoassay (ECLIA). <h3>Results</h3> Osteoporosis according to t- scores of lumbar vertebrae L2-L4 was found to be significantly higher in patients with gout compare to control group (p=0.02). There was no correlation between osteoporosis and the frequency of gout attacts, tophi and disease duration. Osteocalcin levels were detected to be significantly increased in the gout patients compare to control group (p=0.004). Vitamin D levels were similar in gout and control group (p=0.14). Alkaline phosphatase, parathyroid hormone levels were found to be significantly lower in control group compare to gout group (p=0.001). <h3>Conclusions</h3> Gout may increase the risk of osteoporosis and serum osteocalcin levels in clinical practice may be a useful biomarker for osteoporosis. Long-term randomized controlled prospective studies with larger populations are required for the clarification of the relationship between gout and osteoporosis. <h3>Disclosure of Interest</h3> None declared
Novel 2-Phenyl-1-Pyridin-2yl-Ethanone (PpY) Based Iron Chelators Increase Expression of IkBα and Heme Oxygenase-1 and Inhibit HIV-1
Authors: Namita Kumari, Min Xu, Dmytro Kovlaskyy, Subhash Dhawan, Sergei Nekhai
Journal: Blood (2012)
Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue
Authors: Tanjina Kader, David L. Goode, Stephen Q. Wong, Jacquie Connaughton, Simone M. Rowley, Lisa Devereux, David Byrne, Stephen B. Fox, Gisela Mir Arnau, Richard W. Tothill, Ian G. Campbell, Kylie L. Gorringe
Journal: Genome Medicine (2016)

Unlocking clinically translatable genomic information, including copy number alterations (CNA), from formalin-fixed paraffin-embedded (FFPE) tissue is challenging due to low yields and degraded DNA. We describe a robust, cost-effective low-coverage whole genome sequencing (LC WGS) method for CNA detection using 5 ng of FFPE-derived DNA. CN profiles using 100 ng or 5 ng input DNA were highly concordant and comparable with molecular inversion probe (MIP) array profiles. LC WGS improved CN profiles of samples that performed poorly using MIP arrays. Our technique enables identification of driver and prognostic CNAs in archival patient samples previously deemed unsuitable for genomic analysis due to DNA limitations.
Inactivation of Capicua drives cancer metastasis
Authors: Ross A Okimoto, Frank Breitenbuecher, Victor R Olivas, Wei Wu, Beatrice Gini, Matan Hofree, Saurabh Asthana, Gorjan Hrustanovic, Jennifer Flanagan, Asmin Tulpule, Collin M Blakely, Henry J Haringsma, Andrew D Simmons, Kyle Gowen, James Suh, Vincent A Miller, Siraj Ali, Martin Schuler, Trever G Bivona
Journal: Nature Genetics (2016)
The Centromeric Protein, CEN(P)-F, a Marker of Cell Proliferation Is Regulated by Hypoxia in Human Mesenchymal Stem Cells and Their Bone Marrow Stromal Progeny.
Authors: Suzanne M. Watt, Sarah Hale, Dilair Baban, Maria Roubelakis, Meis Moukayed, Jaeseung Lim, Dacey J. Ryan, Kay Davies, Adrian L. Harris, Enca Martin-Rendon
Journal: Blood (2005)
A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management
Authors: Ryota Imanaka, Taiichi Kyo, Kayo Toishigawa, Tetsuro Ochi, Takeshi Okatani, Kouhei Kyo, Mitsuhiro Itagaki, Hisao Nagoshi, Yuta Katayama, Koji Iwato, Hideki Asaoku
Journal: Blood (2015)
CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer
Authors: Chong Li, Shengwu Liu, Ruping Yan, Ning Han, Kwok-Kin Wong, Lei Li
Journal: Theranostics (2016)

Cancer stem cells (CSCs) are considered one of the key contributors to chemoresistance and tumor recurrence. Therefore, the precise identification of reliable CSC markers and clarification of the intracellular signaling involved in CSCs remains a great challenge in fields relating to cancer biology. Here, we implemented a novel chemoresistant prostate cancer patient-derived xenograft (PDX) model in NOD/SCID mice and identified CD54 as a candidate gene among the most highly enriched gene expression profiles in prostate tumors exposed to chronic cisplatin administration. Additional in vitro and in vivo assays showed that CD54 played a critical role in the self-renewal and tumorigenesis of prostate CSCs. Moreover, silencing CD54 greatly reduced the tumorigenesis of prostate cancers both in vitro and in vivo and significantly extended the survival time of tumor-bearing mice in a prostate cancer xenograft model. Dissection of the molecular mechanism revealed that the p38-Notch1 axis was the main downstream signaling pathway in CD54-mediated regulation of CSCs in prostate cancers. Together, these results established that CD54 could be a novel reliable prostate CSC marker and provided a new potential therapeutic target in prostate cancer via CD54-Notch1 signaling.
Thrombopoietin as an Independent Prognostic Marker in Chronic Lymphocytic Leukemia.
Authors: Charles Asa Koller, B. Nebiyou Bekele, Xian Zhou, Charles Park, Zeef Estrove, Susan O’Brien, Michael Keating, Iman Jilani, Francis J. Giles, Hagop M. Kantarjian, Maher Albitar
Journal: Blood (2004)
Circulating microRNAs (miRNAs): Biomarkers for Lung Cancer
Authors: F. Adami, G. Porcile, R. Ridolfi, R. Labianca, S. Palazzo, S. Bretti, P. Gentilini, F. Carbonardi, C. Oliani, E. Aitini
Journal: Annals of Oncology (2015)
CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes
Authors: David K Edwards, Angela Rofelty, Anupriya Agarwal, Stephen E Kurtz, Elie Traer, Patrice Lee, David Chantry, Marc Loriaux, Brian J. Druker, Shannon K. McWeeney, Jeffrey W. Tyner
Journal: Blood (2015)
Detection of Minimal Residual Disease in Patients with Multiple Myeloma by PCR-Based IGH Gene Clonality Analysis Using DNA Extracted From Archival Bone Marrow Slides
Authors: Hiroyuki Takamatsu, Yoshiyasu Ogawa, Noriko Kobayashi, Kazue Obata, Tadashi Narisawa, Kouji Nakayama, Shinji Nakao
Journal: Blood (2011)
SAT0458 Risk Factors for Length of Hospital Stay after Total Knee Arthroplasty: A Five-Year Consecutive Case Series
Authors: K. Kawakami
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The length of hospital stay (LOS) has become a valuable outcome measure of any operation, and it also directly impacts hospital cost. <h3>Objectives</h3> To identify risk factors for LOS after total knee arthroplasty (TKA) in rheumatoid arthritis (RA) and osteoarthritis (OA) patients. <h3>Methods</h3> A retrospective study involving 507 consecutive patients undergoing TKA was conducted during a five-year period from January 2010 to December 2014 (mean age 72 years, 433 females, 82 RA patients, and 58 bilateral TKA). The diagnosis of deep vein thrombosis (DVT) was based on ultrasonography. Multiple linear regression analysis was performed to identify the variables predictive of prolonged LOS and operative time. Multiple logistic regression analysis was performed to analyze the risk factors for postoperative DVT (dependent variables: gender, age, BMI, RA, operative time, antiplatelet agents, cementless TKA, and bilateral TKA). <h3>Results</h3> Of the patients undergoing TKA, the mean LOS was 26 days, and the mean operative time was 73 minutes. The results of the multiple linear regression analysis indicated that female gender (P=0.006), age (P&lt;0.001), higher BMI (P=0.03), operative time (P=0.001), and bilateral TKA (P=0.009) were risk factors for prolonged LOS. A subanalysis of operative time revealed that male gender (P=0.01) and BMI (P=0.03) were associated with longer operative time. A total of 195 (38.5%) cases were DVT positive. Multivariate logistic regression analysis revealed that osteoarthritis (P=0.03) and cementless TKA (P=0.01) were risk factors for DVT after TKA. <h3>Conclusions</h3> Female gender, age, higher BMI, operative time, and bilateral TKA were risk factors for longer LOS. Male gender and higher BMI were risk factors for longer operative time. Osteoarthritis and cementless TKA were risk factors for DVT. Further research investigating the risk factors for longer LOS is needed to reduce total hospital costs. <h3>Disclosure of Interest</h3> None declared
THU0299 B Cell Compartment and Pharmacodynamics of Belimumab in Systemic Lupus Erythematosus: Early Clinical Efficacy by Depletion of CD27- and Increase of CD27+ B Cells: Table 1
Authors: L. Quartuccio, G. De Marchi, F.M. Rossi, F. Zuliani, M. Bond, L. Picco, P. Masolini, F. Rizzolio, S. De Vita
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Belimumab, a human anti-BAFF monoclonal antibody that inhibits soluble BAFF, is effective in systemic lupus erythematosus (SLE), and leads to a partial B cell depletion. However, which subset of B cells may be the main therapeutic target of belimumab in SLE is still unclear. <h3>Objectives</h3> Primary objective of this study was to evaluate the effect of belimumab on the expression of BAFF receptor (BAFFR) on B cells through 12 months of belimumab treatment in SLE, and to correlate BAFFR expression with changes in B cell subsets. <h3>Methods</h3> Twelve consecutive patients with SLE (all female, age 44±7,8 yrs, 12,6±5,4 yrs of disease duration) undergoing belimumab therapy were studied. All patients received at least two immunosuppressors before belimumab. All patients were taking glucocorticoids at baseline [median (range): 7,5 (0–40) mg/day of prednisone or equivalent)], and 11/12 also at least one immunosuppressor. Median SLEDAI-2k score at baseline was 8,5 (range 8–15). Samples were collected and analysed at baseline (T0), month +3 (T3), +6 (T6), +9 (T9) and +12 (T12) for clinical and biological parameters. B cells subsets were characterized by multiparametric flowcytometry on a BD FACSCanto flowcytometer. The expression of BAFFR was also analysed as Mean Fluorescence Intensity (MFI). Parametric or non-parametric tests were used, as appropriate based on variable distribution. Data is reported as mean±standard error. <h3>Results</h3> A transient statistically significant increase of BAFFR MFI was observed from T0 to T3 (p=0,004) and from T0 to T6 (p=0,066) with a subsequent decrease until T12 (table 1). Interestingly, this course was similar to that observed in CD19+CD27+ cell subset (table 1), that showed a transient significant increase at T3 (p=0,014) and T6 (p=0,025) in 9/12 patients, with a subsequent slightly significant decrease from T6 to T12 (p=0,05) in all patients. Globally, a decrease of CD19+ cells was observed from T0 to T12 (p=0,19, table 1). This course is consistent with that observed in the CD27- B cell subset, that showed a decrease from T0 to T3 (p=0,14) and from T0 to T6 (p=0,14), and the decrease was persistent from T6 to T12 (p=0,6). SLEDAI-2k score decreased from T0 to T3 (p=0,007), to T6 (p=0,003) and to T12 (p=0,03) (table 1). <h3>Conclusions</h3> BAFF depletion differently acts on B cell subsets, CD19+27+ subset being able to increase BAFFR and transiently expand themselves, while CD19+27- being more sensitive to BAFF deprivation, and faster decreasing. Thus, early clinical response may be related to the changes in the CD27+/CD27- B cell ratio. <h3>Disclosure of Interest</h3> None declared
PWE-036 The Use of Amino Terminal of Type III Pro-Collagen Peptide (P3NP) to Monitor Methotrexate Associated Liver Fibrosis
Authors: I Haq, R Sikafi, GP Aithal
Journal: Gut (2016)

<h3>Introduction</h3> Methotrexate (MTX) is an important immunosuppressive drug commonly used to treat psoriasis and rheumatoid arthritis. Concern related to the potential of the drug to induce liver fibrosis has led to numerous guidelines on monitoring patients on methotrexate therapy. The amino terminal of type III pro-collagen peptide (P3NP) is an extension peptide that is cleaved and liberated into extracellular fluid and hence is a biomarker for collagen turnover. Increased levels occur during tissue repair and fibrosis, hence in principle P3NP has been used to monitor patients for potential adverse effect of hepatic fibrosis. <h3>Methods</h3> We reviewed all requests for P3NP received by clinical biochemistry service at Nottingham University Hospitals between 2010 and 2015. We assessed how the results of P3NP were acted upon, what further tests and investigations were performed on patients where raised P3NP were reported. A total of 7319 assays were analysed corresponding to 495 patients. The data were analysed to see what proportion of positive results went on to have a Fibroscan, liver biopsy and to see whether histological findings correlate with P3NP level. As well as basic demographic data, we looked at co-morbidities, imaging, transient elastography and other risk factors for liver disease. <h3>Results</h3> Of the 495 patient records examined 185 (37.3%) had a raised P3NP levels (&gt;8 microg/L); of these, 33 (17.8%) were referred to hepatologists leading to 27/33 (69.7%) investigated with transient elastography and 8 (24.2%) having liver biopsy. Of those who had liver biopsy 6/8 (75%) showed NASH with early fibrosis and 25% showed advanced fibrosis from NAFLD; in addition to methotrexate therapy, all of these patients had one or more risk factors for NAFLD. A mean P3NP value of 11.4 correlated with NASH with any fibrosis and 16.4 microg/L correlated with advanced fibrosis. <h3>Conclusion</h3> Despite wide spread use of P3NP, raised P3NP are not investigated adequately. Although small number of patients undergoing liver biopsy had significant histological abnormality ranging from NASH to advanced fibrosis, all had additional risk factors for NAFLD indicating that MTX treatment could therefore be stratified according to co-morbid risk factors. <h3>Disclosure of Interest</h3> None Declared
Immunoglobulin (Ig) Variable Gene Usage Identifies a Subset of Unmutated Chronic Lymphocytic Leukemia (CLL) Patients Expressing 51p1-Like alleles and a Particularly Unfavorable Prognostic Outcome.
Authors: Emanuela M. Ghia, Anna Guarini, Francesca R. Mauro, Massimo Gentile, Irene Della Starza, Daniela Capello, Gianluca Gaidano, Robert Foa
Journal: Blood (2004)
FRI0397 The Diagnostic Value of The Symptom of Inflammatory Back Pain in Axial Spondyloarthritis in The Rheumatology Setting
Authors: D. Poddubnyy, I. Spiller, J. Listing, J. Braun, J. Sieper, M. Rudwaleit
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Inflammatory back pain (IBP) as a symptom has been shown to perform effectively for selecting patients in primary care/orthopaedic settings for referral of chronic back pain patients to the rheumatologist for further diagnostic work-up. IBP is also being used as a diagnostic test of axial spondyloarthritis (axSpA) by rheumatologists, but no validations studies have been performed so far with IBP as a diagnostic tool. <h3>Objectives</h3> The aim of the DIVERS study was to evaluate the diagnostic value of the IBP symptom in axSpA in the rheumatology setting. <h3>Methods</h3> A total of 405 consecutive patients referred to a rheumatologist because of chronic back pain starting at an age &lt;45 years and suspicion of axSpA were included in this multicentre study. A questionnaire containing all relevant IBP parameters was first answered by the patient, followed by a rheumatologist blinded for presence or absence of other SpA features and for the diagnosis, and finally by the rheumatologist responsible for the diagnosis. A global evaluation of IBP by rheumatologists, and IBP according to the previously published Calin9s, Berlin and ASAS criteria as well as single items of IBP were compared regarding their diagnostic performance. <h3>Results</h3> The diagnosis of definite axSpA was made in 180 (44.4%) patients (88 with ankylosing spondylitis and 92 with non-radiographic axSpA). The sensitivity, specificity and the positive likelihood ratio of IPB for the axSpA diagnosis was 81%, 44%, and 1.5, respectively, if globally assessed by the blinded rheumatologist, and 90%, 58% and 2.2, respectively, if globally assessed by the diagnosing rheumatologist - table. There was no clear superiority of any of the three criteria sets regarding sensitivity for the axSpA diagnosis with an overall sensitivity of about 80% and specificity between 25% and 45% if symptoms were assessed by a rheumatologist - table. The performance of the criteria sets based on patient9s own evaluation of IBP symptoms was generally lower. No single IBP parameter showed superiority regarding sensitivity or specificity in comparison to the criteria sets. <h3>Conclusions</h3> IBP demonstrated high sensitivity but rather modest specificity for the diagnosis of axSpA among patients with chronic back pain referred to a rheumatologist. A resulting moderate diagnostic value of IBP in the rheumatology setting is likely to be counterbalanced by increase in the pre-test probability of axSpA in this patients population. <h3>Disclosure of Interest</h3> None declared
Detection of TP53 Mutations in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). a Comparison Between a Functional Method (FASAY) and Next Generation Sequencing (NGS)
Authors: Cécile Bally, Aline Renneville, Lionel Adès, Claude Preudhomme, Hugues de Thé, Pierre Fenaux, Jacqueline Lehmann-Che
Journal: Blood (2014)
Effect of a Decision Aid on Access to Total Knee Replacement for Black Patients With Osteoarthritis of the Knee
Authors: Said A. Ibrahim, Marissa Blum, Gwo-Chin Lee, Pekka Mooar, Elina Medvedeva, Aliya Collier, Diane Richardson
Journal: JAMA Surgery (2016)

Black patients with advanced osteoarthritis (OA) of the knee are significantly less likely than white patients to undergo surgery. No strategies have been proved to improve access to surgery for black patients with end-stage OA of the knee.